Literature DB >> 169990

Disposition of cytosine arabinoside (NSC-63878) and its metabolites: a pharmacokinetic simulation.

P F Morrison, T L Lincoln, J Aroesty.   

Abstract

A computer-based model of the pharmacokinetics of cytosine arabinoside (ara-C) and its active metabolite, ara-CTP, has been developed. This model, which is an intracellular extension of the Bischoff-Dedrick model of multi-organ pharmcokinetics gives predictions which are in agreement with the recent measurements of Chou et al on tissue concentrations of ara-CTP and Borsa et al on blood levels of ara-C. It is shown that the ara-CTP halving time in tissue is much greater than the ara-C halving time in blood because of low tissue levels of phosphatase. For a single dose at the LD10 level in mice, significant splenic DNA inhibition is calculated to occur for 26 hours, while the ara-C levels are negligible in 6 hours. The calculated duration of cytostatic effect at lower dosages (2.5 mg/kg) is 10 or 12 hours, while ara-C blood levels are negligible within 3 hours. Implications for cell kinetics and scheduling studies are also briefly described.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 169990

Source DB:  PubMed          Journal:  Cancer Chemother Rep        ISSN: 0069-0112


  2 in total

Review 1.  A review of the applications of physiologically based pharmacokinetic modeling.

Authors:  K J Himmelstein; R J Lutz
Journal:  J Pharmacokinet Biopharm       Date:  1979-04

Review 2.  Physiologically based pharmacokinetic models for anticancer drugs.

Authors:  H S Chen; J F Gross
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.